The QualityStocks Daily Newsletter for Wednesday October 21st, 2009 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters


OTC Reporter (JUNP)


Penny Stock Chaser (PLMO)


Willy Wizard (SPNG)

The QualityStocks Daily

BioNeutral Group, Inc. (BONU)

Wall Street Grand and Another Winning Trade reported this month on BioNeutral Group, Inc. (BONU Stock Rich, Momentum Traders, Micro Cap Pulse, Micro Stock Profit, Beacon Equity Research, Greenbackers, OTC Picks, Dubai Penny Stocks, The Best Stock Pick, StockEgg.com, Penny Invest, The Dean, 24-7 Stock Alert, Global Equity Report, The Upturn Stock, Penny Stock Explosion reported earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

BioNeutral Group, Inc. is a specialty chemical technology based Life Science Company. BioNeutral Group, Inc. intends to commercialize a combinational chemistry-based technology. This technology can neutralize harmful environmental contaminants, toxins, and dangerous microorganisms. These include bacteria, viruses, mold, fungi, and spores. Trading on the OTCBB, the Company has their headquarters at the New Jersey Institute of Technology/EDC in Newark, New Jersey.

The Company's formulations include Ygiene™ and Ogiene™.  These are eco-friendly and include natural and common ingredients, which are in baby products and in every day foods. The Company has combined these widely used compounds in highly specialized ways to create products that significantly enhance disinfecting and cleaning results. BioNeutral's proprietary platform technology has proven effective in surface, water, and airborne applications.  Products include BioNeutralizers and ChemoNeutralizers.

BioNeutralizers, based on the Company's proprietary Ygiene™ platform formulation, disinfect, decontaminate, and sterilize. BioNeutral's corporate mission is to bring to market the broadest-based, fastest acting, most effective and safest anti-microbial known. The Company believes this class of products has important applications for Healthcare Facilities, Consumers / Household use, Industrial Applications, as well as Military / Homeland Security.

ChemoNeutralizers, based on the Ogiene™ formula, irreversibly bind chemical contaminants and toxin molecules rendering them harmless. Applications for this product include industrial pollution, environmental contaminants, and protection against chemical weapons of mass destruction.

Recently, BioNeutral Group, Inc. announced that independent lab test results conducted at Microbiotest Inc. of Sterling, Virginia demonstrated that Ygiene™ Consumer Grade Antimicrobial totally eradicated the H1N1 Swine Flu Virus in 20 seconds. This is a significantly milder and diluted variation of the Ygiene™ Hospital Grade Formulation. The independent testing shows that Ygiene™ Consumer Grade Antimicrobial equaled the performance of the Company's hospital grade formulation. It showed that the formulation is extremely effective against the Swine Flu. It is one of a few antimicrobials actually tested against the specific H1N1 Swine Flu Virus.

On September 11, 2009, BioNeutral Group, Inc. announced that independent lab test results conducted at Microbiotest Inc. of Sterling, Virginia, demonstrated that Ygiene® antimicrobial diluted 1 to 10 with water can totally eradicate the H1N1 Swine Flu virus in 59 seconds on an unclean, soiled surface. The test was performed to determine the effectiveness of Ygiene® specifically against the 2009 H1N1 (swine flu) virus on surfaces that are not pre-cleaned.

BioNeutral Group, Inc. (BONU) closed today's session at $0.77 up 20.12 percent. Volume was 195,881.

Averion International Corp. (AVRO)

We are highlighting Averion International Corp. (AVRO), here at the QualityStocks Daily newsletter.

Trading on the OTCBB, Averion International Corp. is an international clinical research organization. Their corporate focus is on providing clinical research services and solutions for the drug development lifecycle. The Company has expertise in supporting global clinical trials for pharmaceutical, biotechnology, and medical device companies. The Company's well-designed trials span the development lifecycle from "first-in-man" through regulatory approval and beyond. The Company is a clinical research partner for enterprises around the world. Averion has their headquarters in Southborough, Massachusetts.

Averion International Corp. evolved through a series of acquisitions. Each of these acquisitions involved the addition of a high-quality clinical research organization (CRO) with major expertise and a proven record of accomplishment.  The Company's acquisition strategy began more robustly in 2005. This was when the Company, then a life sciences staffing business known as IT&E International Group, Inc. (IT&E), acquired their first stand-alone CRO business. 

In 2005, IT&E acquired Millennix, Inc., an Oncology-focused CRO. In 2006, IT&E acquired Averion Inc., a CRO that began operations in 1983 as Boston Biostatistics, Inc., which was co-founded by Philip T. Lavin, Ph.D. and David Schoenfeld, Ph.D.  In 2001, Boston Biostatistics changed their name to Averion Inc., to reflect the Company's change in scope.  In 2006, following the acquisition, the combined Company changed their name to Averion International Corp. and ticker symbol to AVRO.

In 2007, Averion divested the IT&E staffing business segment in order to focus on growing their core clinical research business.  Also in 2007, Averion acquired Hesperion AG, a 10-year old, Switzerland-based CRO having significant experience in supporting global Cardiology, Oncology, and Vaccines trials. Hesperion's acquisition doubled the size of Averion and significantly expanded the Company's worldwide reach in Europe and globally.

Averion International's major therapeutic categories include oncology, cardiology, and medical devices. The Company's main competencies are in product-agency registration support, trial design, site selection, and project management. Their competencies are also in medical and site monitoring, data management, biostatistical analysis, pharmacovigilance, medical writing, metrics development, and full clinical trial management and consulting services.

On September 5, 2009, Averion International Corp. announced that they filed an information statement with the Securities and Exchange Commission (SEC) regarding their plan to go private. A majority of the Company's common shareholders have approved an amendment to the Company's certificate of incorporation to affect a reverse stock split in a ratio of 20,500 for 1.

Averion International Corp. (AVRO) closed today's session at $0.0051 up 2.00 percent. Volume was 1,420,000.

ChromaDex Corp. (CDXC)

We are highlighting ChromaDex Corp. (CDXC), here at the QualityStocks Daily Newsletter.

Headquartered in Irvine, California, ChromaDex Corp. is a leader in phytochemical reference standards and contract research. The Company established to become the market leader in the creation and supply of botanical reference standards along with related phytochemical products and services. Due to the need for reference standards and other quality assurance methods to identify active substances, drug/compound interactions, and the presence of toxic or adulterating materials, ChromaDex™ provides the tools necessary to help with the quality and control of the market. ChromaDex Corp. trades on the OTCBB.

The Company's primary focus is to create industry-accepted information, products, and services to every layer of the functional food, pharmaceutical, personal care, and dietary supplement markets. They offer the most extensive phytochemical catalog in the world. ChromaDex provides a broad range of analytical services, contract isolation, microbiological, process development, bioassay services, and consulting. These all center on their expertise in natural products. They provide a wide range of services to food, beverage, cosmetic, dietary supplement and pharmaceutical companies looking for expertise in natural products based services.

In June, ChromaDex Corp. announced that the National Science Foundation awarded the Company a $100,000 Small Business Innovation Research (SBIR) Grant. This grant is to further the development of several plant-based antioxidants called anthocyanins for commercial use in pharmaceutical, nutraceutical, functional food, natural chemical and cosmetic products. The Phase I proof of concept grant is effective July 1 through December 31, 2009.

ChromaDex also reported that the National Institutes of Health established a Blanket Purchase Agreement (BPA) with the Company. The BPA covers all products and services offered by ChromaDex. This includes botanical reference materials, phytochemicals, bulk chemical production, analytical testing services, analytical method development, and contract research, isolation of compounds, chemical synthesis, and natural product libraries. The BPA makes it easier for the various Institutes within the National Institutes of Health to do business with ChromaDex Corp.

In July, ChromaDex announced that they awarded exclusive distributor rights to LGC Promochem India Pvt. Ltd. This is for the sale of their phytochemical reference standards in India. This partnership builds upon the long-standing relationship between ChromaDex Corp. and their exclusive European distributor, LGC Standards.

ChromaDex Corp. (CDXC) closed Wednesday's trading session at $0.32 up 6.67 percent. Volume was 15,000 shares.

Cannabis Science, Inc. (CBIS)

Today, Standout Stocks reported on Cannabis Science, Inc. (CBIS), AlphaTrade, HotOTC.com, Stock Rich, Cool Penny Stocks, SmallCap Voice, OTC Picks, Penny Invest, StockEgg.com, Market Alerts, Stock Stars did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTCBB, Cannabis Science Inc. is an emerging cannabis pharmaceutical company. They are at the forefront of medical marijuana research and development. With headquarters in Palm Springs, California, the Company works with world authorities on phytocannabinoid science targeting critical illnesses.

Phytocannabinoids - also called natural cannabinoids, herbal cannabinoids, and classical cannabinoids - are only known to occur naturally in significant quantity in the cannabis plant. They are concentrated in a viscous resin produced in glandular structures known as trichomes, and are most prevalent in the flowers of the female plants.

Cannabis Science, Inc.'s dedication is to the creation of cannabis-based medicines. Cannabis Science, Inc. adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. They are working to create these medicines both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Cannabis has found use medicinally for thousands of years; however, until very recently little was known about how it actually worked. Some well-known uses of cannabis are for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include chronic pain, and reducing muscle spasms associated with neuromuscular disorders. Some current uses are poorly understood, including its effectiveness in alleviating certain autoimmune disorders such a Crohn's Disease.

Today, Cannabis Science Inc. announced that they added four prominent attorneys, who specialized in marijuana-related cases, to their Policy Advisory Board. This is as medical marijuana legalization moves closer with President Obama's New Medical Marijuana Policies and initiatives.

Cannabis Science Inc., President and CEO, Dr. Robert Melamede Ph.D., stated, "We will continue to add teams of industry experts to our Company. We are honored that our Policy Advisory Board is expanding with some of the nation’s top medical marijuana attorneys. Obviously, we are operating in an area where the laws are evolving very rapidly, and we are pleased to have so many experienced attorneys on board, helping steer the company through these complex and evolving opportunities for us."

Today, Cannabis Science, Inc. (CBIS) closed at $0.5150 up 6.19 percent. Volume was 80,584.

Goldrich Mining Company (GRMC)

We are highlighting Goldrich Mining Company (GRMC), here at the QualityStocks Daily Newsletter.

Founded in 1959, Goldrich Mining Company engages in the business of the discovery and mining of mineral deposits. The Company primarily focuses on properties containing gold, as well as associated base and precious metals. Formerly known as Little Squaw Gold Mining Company, Goldrich Mining Company has their headquarters in Spokane, Washington. They trade on the OTC Bulletin Board.

Goldrich holds interest in the Chandalar property covering 14,800 acres located in Alaska. The Chandalar district is widely recognized as the easternmost mineralized area within a Devonian age schist belt that extends along the south flank of the Brooks Range. This belt includes famous deposits such as Cominco's Red Dog zinc mine, the largest zinc deposit in the world. It also includes the prolific Ambler volcanogenic massive sulfide (copper & zinc) district, now controlled by Nova Gold. Gold was first discovered in Chandalar in 1905. The Chandalar district's recorded gold production is more than 84,000 ounces.

This past July, Goldrich Mining Company initiated alluvial gold production at their Chandalar property, located 200 miles north of Fairbanks, Alaska. The plant is capable of processing up to 200 cubic yards of gold-bearing gravels per hour.

On October 8, 2009, Goldrich Mining Company reported the successful completion of their 2009 alluvial gold mining test on Little Squaw Creek at the Chandalar property. The pilot program involved a full-scale mining test that produced 593.5 ounces of placer gold. The test mining yielded valuable mining and engineering data. This will enable Goldrich Mining to speed-up the project into commercial production in the spring of 2010. The mining objectives of the pilot operation were completely fulfilled.

Richard Walters, President of Goldrich Mining Company, stated, "This was a demonstration project that proved we can do it. It's an unqualified success. We completed the first and most difficult phase of operations and set the stage for ongoing gold production."

Goldrich Mining Company (GRMC) closed today's session at $0.3505 up 0.14 percent. Volume was 33,136.

JayHawk Energy, Inc. (JYHW)

Recently, Street Authority Financial, Small Cap Investor, Schaeffer's, MicroCap Gems, Investor Spec Sheet, and The Online Investor reported on JayHawk Energy, Inc. (JYHW).  Daily Profit, Stealth Stocks, NanoCap Gems, Investment House, Contrarian Press did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

JayHawk Energy, Inc. is a managed risk oil and gas exploration/exploitation, development, and production company. The Company focuses their activities on two major projects. These projects are in the Cherokee Basin, Kansas, and the Williston Basin, North Dakota. JayHawk Energy, Inc. trades on the OTCBB. They have their corporate headquarters in Post Falls, Idaho.

Founded in 2004, JayHawk Energy, Inc. formerly went by the name Bella Trading Company, Inc. They changed their name to JayHawk Energy, Inc. in June 2007. The Company's current focus is on the exploration, drilling, and development of approximately 45,000 acres known as the Uniontown and Girard projects located in the Cherokee Basin, Bourbon, and Crawford Counties, Kansas. Adjacent to these projects is their wholly owned pipeline, tied to sales. In addition, JayHawk is currently utilizing a light crude oil producing property in the Williston Basin, Candak County, North Dakota.

In August, JayHawk Energy, Inc. announced that they signed a letter agreement with DK True Energy Development Limited. The agreement allows True Energy to earn up to an 85 percent working interest in JayHawk's Coal Bed Methane project in southeast Kansas. This is through paying JayHawk $500,000 and spending a minimum of $1,300,000 over a three-year period.

True Energy will bear the entire cost to develop the project over the next three years. JayHawk will continue to own 100 percent of their 18-mile gas pipeline in southeast Kansas and will continue to draw 100 percent of the revenue from the pipeline.

Last month, JayHawk Energy, Inc. provided an operational update regarding their Uniontown project and their Girard project, and several other shallow oil opportunities within their existing acreage exploitable via Enhanced Oil Recovery (EOR). The current target for development within the Uniontown and Girard projects is the shallow gas (75-300 m) potential of the area. They are also holding the leases for potential future development of coal-bed methane (CBM), conventional oil, and gas resources.

JayHawk Energy, Inc. (JYHW) closed Wednesday's session at $0.28 up 5.66 percent. Volume was 136,699.

Sanguine Corporation (SGUI)

We are highlighting Sanguine Corporation (SGUI), here at the QualityStocks Daily Newsletter.

Sanguine Corporation is a company whose primary focus is the development of PHER-O2, a perfluorocarbon (PFC) emulsion with oxygen carrying properties. PHER-02 has immediate applications as an intravenous supplement to red blood cell function. Trading on the OTCBB, Sanguine Corp. began in 1974. They have their headquarters in Pasadena, California.  

Sanguine Corporation is a well-established organization with experts in the field of synthetic blood chemistry and development. PHER O2 is a second-generation formulation of the perfluorocarbon (PFC) emulsion, Fluosol, a product developed, and FDA approved and marketed under the direction of Dr. Thomas Drees, current Chairman and CEO of Sanguine. Dr. Thomas Drees was a leader in the creation of Fluosol®, the only synthetic blood supplement approved to date for human use by the United States Food and Drug Administration (FDA). The FDA approved Fluosol for angioplasty use only in 1989. Fluosol was withdrawn from the market in 1994. This was due to the difficulty of storing it frozen and then bringing it to ambient temperature prior to use.

PHER-O2 consists of perfluoro-decalin molecules or synthetic red blood cells, purified water, and a synthetic and fluorinated surfactant to hold the emulsion together. PHER-O2 is under Phase II clinical trials and has oxygen-carrying capacity. Its various medical applications would include ophthalmic retinal surgery, angioplasty, and transportation of pancreas islets for treatment of diabetes.

Medical applications would also include external oxygenation of infection, ischemic tissue, and diabetic ulcers. PHER-O2 would also find use for Alzheimer's, oxygenation of cancerous tumors, nuclear magnetic resonance imaging, CAT scans, and cardioplegia. In addition, it would find use for the treatment of heart attacks, strokes, head and neck tumors, and hemorrhagic shock.

In March of this year, Sanguine Corporation announced that the Company signed a Letter of Commitment to license their PHER-O2 technology to Rockland Technimed Ltd. This is for a collaborative effort to enhance significantly stroke and tumor diagnosis and treatment. Technimed's MRI Imaging technology and product Oxy-17® effectively renders an unaltered MRI scanner into a PET, PET/CT like metabolic imager using innovative, ultra pure Oxygen, isotopically enriched and naturally occurring in atmospheric air, delivered to target tissue of interest. The ability to follow cellular respiration in real-time using an unaltered MRI in these patients is a significant development in the management of these patients.

On October 6, 2009, Sanguine Corporation announced that they would change the name of their wholly owned subsidiary, Sanguine Life Sciences, to SGN Life Sciences. This name change is to reflect better the subsidiary's intended business model.

Company spokesperson, Mr. Frank Marra, explained, "When we decided to set up the Sanguine Life Sciences subsidiary we did so primarily for the purpose of seeking partnering relationships or merger candidates for PHER-O2. However, it has become clear that the scope of the subsidiary can represent much more opportunity to the Company. We intend to use the SGN Subsidiary to take advantage of market opportunities that have presented themselves to us; which includes, but is not limited to, PHER-O2 potential collaborations."  

Sanguine Corporation (SGUI) closed today's session at $0.23 up 53.33 percent. Volume was 329 shares.

MabCure, Inc. (MBCI)

Today, The Best Newsletters, Another Winning Trade, Investment House, Daily Profit, and Market FN reported on MabCure, Inc. (MBCI), Small Cap Network did yesterday. Street Insider, ChartAdvisor.com, Stock Research Newsletter, Street Authority Financial, SmallCapInvestor.com, Ceocast News, Investors Alley, Topgun Stockpicks, and Stock Stars did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.

MabCure, Inc. is a biotechnology company using their proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer. The Company's vision is to change the perception of cancer as being a largely incurable disease. MabCure's initial goal is to develop their novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage. The Company has their head office in New York, New York, as well as an office in Belgium. MabCure, Inc. trades on NASDAQ's OTC Bulletin Board.

MabCure is developing their proprietary technology as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure hybridoma technology exhibits several important advantages. The basis of Classic Hybridoma technology is on the generation of immortal "hybrid cells" (hybridoma), which follows the fusion of antibody-producing B-cells with myeloma tumor cells. Each hybridoma continuously "manufactures" a single type of (monoclonal) antibody. 

MabCure "re-engineered" the classic hybridoma technology into a highly efficient and optimized one. Prior identity of cancer antigen(s) is not required for generating MAbs against these antigens. Antigens are preserved in their natural conformations; the resulting Mabs are able to better recognize and bind more selectively to tumor cells. In addition, unlimited quantities of antibodies are produced against a selected cancer target. 

MabCure's first goal is the development of simple diagnostic tests. These are for the early detection of ovarian, prostate, colorectal, and breast carcinomas. The Company's strategic plan also calls for the application of their proprietary cancer-specific Mabs in three additional areas. These are the imaging of cancer, immunotherapy of cancer, and the discovery of novel cancer markers (tumor specific antigens), which can lead to the development of potent anti-cancer drugs.

On September 29, 2009, MabCure, Inc. announced that they reached another development milestone. This is through the creation of their MAbs against Colorectal Cancer (CRC). After further characterization, they plan to explore the utility of these MAbs. This is concerning both the early diagnosis of CRC (in blood or feces specimens), as well as imaging agents for detecting micrometastatic disease during surgery and the detection of cancerous polyps during colonoscopy.

MabCure, Inc. (MBCI) closed Wednesday's trading session at $1.145 up 8.02 percent. Volume was 858,642.

The QualityStocks Company Corner

Clenergen Corp. (CRGE)
Consorteum Holdings, Inc. (CSRH)
Muscle Flex Inc. (MFLI)
Advanced Visual Systems (AVSC)

Simulated Environment (SMEV)
Omnicity Corp (OMCY) BLOG
Clenergen Corporation (CRGE) BLOG

Clenergen Corp. (CRGE)

The QualityStocks Daily Newsletter would like to spotlight Clenergen Corp. (CRGE) Today, Clenergen Corporation closed trading at $1.30, which was up 8.33 percent. Their volume today was 208,830 shares.

The Chennai-based Clenergen Corporation India Private Limited, a wholly owned subsidiary of Clenergen Corporation, has reached agreement on the terms to acquire a 1.5MW/Hr biomass power plant in Namakkal, Tamilnadu that will be operational by yearend 2009.

Clenergen Corporation (CRGE) is focused on using a proprietary biomass process to generate renewable electricity. The company has identified two fast growing species of tree and applied a proprietary Tree Adaption Process for rapidly increasing the growth rate 30-40%. This substantial growth rate will enable the production of an economically viable source of feedstock/biomass for creating a renewable source of electricity.

The company anticipates the implementation of a 71MW per hour biomass power plant in Tamilnadu, India, which will be phased over a 42 month period. It is expected that by 2010, the power plant will generate 15MW per hour. Utilizing 6,500 acres of land for the cultivation of feedstock, the project is scalable and capable of expanding to 121MW per hour within a 5 year period.

Because the company will be using renewable biomass, organic material derived from plant matter not related to food production, it is able to produce clean, sustainable energy without endangering the food supply. Additionally, unlike fossil fuels that only add CO2 to the atmosphere, biomass generates positive carbon emissions credits through the process of photosynthesis.

Clenergen Corporation (CRGE) is backed by an experienced management team with a track record of success and operational expertise. The company has also established third party partnerships to enable the business to achieve its business goals and enable it to meet or exceed its financial forecasts and projections. To date, Clenergen has begun operations in the following markets: Guyana, Ghana, Uganda, Brazil Russia and South Africa. Disclaimer

Clenergen Corp. Blog

Clenergen Corp. News:

Clenergen plans biomass-based projects

Clenergen Corporation (OTCBB:CRGE) Signs Memorandum of Agreement With Leading Scientific Research and Development Company

Clenergen Corporation (OTCBB: CRGE) Appoints Dale Shepherd Chief Financial Officer and Abillish Kamti as Chief Financial Officer of Clenergen India Private Limited

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH) Today, Consorteum Holdings, Inc. closed trading at $0.19, which was up 11.76 percent. Their volume today was 5,600 shares.

Consorteum Holdings, Inc. (CSRH) announced that they signed a Letter of Intent with Tactical Connections Inc. to provide various financial services to major tier one U.S., Canadian, and European manufacturing and retail industries.

Consorteum Holdings, Inc. (CSRH) is focused on providing financial services, electronic transaction processing and management services to financial institutions, healthcare, government, public and private sector companies. The company's services provide customized, innovative technology solutions that create, augment and enhance their clients' existing financial, payment and transactional processing systems.

The company offers clients a long-term strategic plan utilizing the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create exceptionally customized programs. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new revenues.

Consorteum's strategy is to capitalize on the global opportunities within the growing financial services, payment and transaction processing marketplace. The utilized business model generates revenues on every transaction touched, thus providing long-term, sustainable income. The company has strategically designed its business initiatives to create significant repetitive transactions on an ongoing basis. Additional company revenues are generated from consulting services, project minimums and management fees.

The company is jointly led by CEO Craig Fielding and President & COO Quent Rickerby. Mr. Fielding brings a wealth of expertise in the payments industry, in both local and international payment processing, along with HR-specific business management expertise, leadership, customer development and acquisition skills. Mr. Rickerby brings over two decades of business management, international and domestic sales experience, new company start-up, payment processing, project management, business development, negotiations, relationship management and strategic company direction.Disclaimer

Consorteum Holdings, Inc. Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Inc. Provides Corporate Update

Consorteum Holdings Inc. New Partnership Provides Competitive Merchant Discount Rates

Consorteum Holdings Inc. Forms Joint Venture to Capitalize on Emerging International Markets

Muscle Flex Inc. (MFLI)

The QualityStocks Daily Newsletter would like to spotlight Muscle Flex Inc. (MFLI). Today, Muscle Flex Inc. closed trading at $0.0180, which was down 10.00 percent. Their volume today was 806,525 shares.

Muscle Flex Inc. (MFLI) announced that they have completed filming of the BUDDY Table Caddy™ and The Beagle StepFit™ Pedometer infomercials and are preparing for the November 2009 launch.

Muscle Flex Inc. (MFLI) is a leading edge fitness, health and lifestyle company focused on developing exciting brands and new products to market using direct response TV advertising and infomercials as well as cutting edge brand and image marketing. The company has designed all its products with the average person's lifestyle in mind.

Muscle Flex Inc. VATA Brasil sports and active wear collection is an ultra comfortable active wear line that utilizes superior moisture control fabric. The VATA Brasil OneFit fabric is an amazing innovation in sporting wear apparel, offering the advantages of being lightweight, highly elastic, and having four times the filaments than regular fabric.

The company’s newest product, The BUDDY Tablet Caddy™, is a personal, compact and portable tablet caddy with three individual compartments and a digital timer to remind users when it’s time to take vitamins or prescriptions. The pharmacist approved tablet caddy ensures the maximum effectiveness of all medications and supplements.

Founder and CEO Danny Alex leads the company with nearly three decades of experience in the health, fitness and athletic lifestyle. Since a young age, regular exercising and maintaining a healthy lifestyle has been a key part of Danny’s life. Today, it is his passion to help others get excited about themselves through fitness and healthy living. Disclaimer

Muscle Flex Inc. Blog

Muscle Flex Inc. News:

Muscle Flex Developing a Strong Product Portfolio in the "Water" Category to Include Filtration, Bottled Water and Health Infused Water

Muscle Flex(R) to Join the Official Latin GRAMMY(R) Awards Talent Gift Lounge November 3-5 in Las Vegas to Showcase Its Muscle Flex VATA Brasil(TM) Sports & Active Wear Collection to Coincide With the Release of the BUDDY Tablet CADDY(TM) and Beagle StepFit(TM) Commercial Launches

Muscle Flex(R) Releases Its "In the Raw(R)" Logo Designs

Advanced Visual Systems Inc. (AVSC)

The QualityStocks Daily Newsletter would like to spotlight Advanced Visual Systems Inc. (AVSC) Today, Advanced Visual Systems Inc. closed trading at $0.64, which was up 25.49 percent. Their volume today was 320,136 shares.

Advanced Visual Systems Inc. (AVSC) develops and distributes software products that are used in multiple sectors of the business and technical industries to present various forms of data in easily understandable graphic representations. Offering a complete line of software products and consulting services, the company is widely recognized as the data visualization industry leader, boasting over 2,500 international customers.

The company has distinguished itself from other companies in the fast-growing data visualization and analytic fields through its comprehensive range of software offerings and sixteen years of product innovation. Together, these competitive advantages have enabled AVS to capitalize on a growing marketplace for graphics-based analytic technology.
Advanced Visual Systems’ premiere products include OpenViz, a data visualization engine designed to provide interactive visual analysis to business applications; AVS/Express, a software development system designed for programmers as well as individual end-users; Toolmaster, a comprehensive graphics library that is used to create charts and graphs; and Gsharp, a Windows and Unix-based software product that generates technical charts and graphs.

The company collaborates with its partners to provide clients with every possible technology advantage. These partners include Microsoft, Oracle, Hewlett-Packard, Sun Microsystems, and other industry leaders. With a comprehensive product line and an experienced management team, no other software company offers the range of developer-friendly products and capabilities as AVS.

Advanced Visual Systems Inc. Blog

Advanced Visual Systems Inc. News:

Advanced Visual Systems Celebrates 18 Years of Data Visualization Technology Leadership

Advanced Visual Systems Improves Real-Time Performance Monitoring for Major Global Enterprise

Data Visualization Software from Advanced Visual Systems Adds Powerful Functionality to Business Intelligence Dashboards

eDOORWAYS Corporation (EDWY)

The QualityStocks Daily Newsletter would like to spotlight eDOORWAYS Corporation (EDWY) Today, eDOORWAYS Corp. closed trading at $0.0529, which was up 23.02 percent. Their volume today was 5,432,471 shares.

eDOORWAYS Corp. (EDWY) announced it is scheduled to present at ISTEC's (Ibero-American Science and Technology Education Center) 17th annual General Assembly, held the week of October 26 - 30, 2009, on the Campus of the University of New Mexico (UNM) in Albuquerque, NM.

eDOORWAYS Corp. (EDWY) has released the second in a series of video vignettes aimed at introducing eDoorways' platform, educating its target audience on the functionality and uses of its doorways, as well as communicating the company's progress to shareholders.

eDOORWAYS Corp. (EDWY) is committed to solving lifestyle problems for consumers while driving traffic to suppliers and service providers who offer innovative merchandise and solutions. The company has the potential to completely change the future landscape of business by offering a unique and comprehensive service that saves consumers valuable time and money. By uniting a consumer with the larger global consumer community, retailers, and manufacturers in an effective new way, eDOORWAYS promotes “dynamic” commerce, as opposed to the static model currently in existence.

The Company plans to capitalize on several emerging new trends. These newly created opportunities include: the large success of Web 2.0 Internet community service offerings such as MySpace, the movement towards niche marketing and targeted advertising, the introduction of new technologies that enable instantaneous, online presentation of information, and the rising consumer preference for using the Internet to gain information before making purchasing decisions.

eDOORWAYS plans to introduce local services using a city-by-city strategy that will minimize capital requirements, reduce staffing requirements, and optimize generated revenues. Ten major cities are targeted for launch in the first year. Advertising, PR campaigns and viral word-of-mouth will be used to give a public presentation to experts as well as educate the market.

The key benefits offered to consumers include a higher level of engagement with vendors, trusted information from other consumers, and superior customer service. Revenues will be generated through advertising placement fees, premium services, preferential placement fees, and a percentage of sales transactions. eDOORWAYS' progressive vision and professional management team makes it an attractive investment opportunity. Disclaimer

eDOORWAYS Corporation Blog

eDOORWAYS Corporation News:

eDoorways Invited to Demonstrate on a World Stage at the Ibero-American Science and Technology Education Center's XVII Annual General Assembly

eDoorways Releases Third Video Vignette, and Provides New Updates to Shareholders

eDoorways Signs Letter of Intent to Purchase Mobile Video Transceiver Technology and Expertise of Ian Mitchell to Create New Subsidiary

Simulated Environment Concepts, Inc. (SMEV)

The QualityStocks Daily Newsletter would like to spotlight Simulated Environment Concepts, Inc. (SMEV). Today, Simulated Environment Concepts, Inc. closed trading at $0.0050, which was up 21.95 percent. Their volume today was 25,000 shares.

Simulated Environment Concepts, Inc. (SMEV) is focused on manufacturing and distributing their patented SpaCapsule® as well as continued innovation in the areas of anti-aging, cosmetics, relaxation, cellulite reduction, and weight loss. Finding use in numerous environments such as relaxation centers, golf clubs, ski lounges, gyms, and health clubs, the SpaCapsule® provides next generation de-stressing and relaxation.

The company’s founders, Dr. Ella Frenkel and Dr. Ilya Spivak, initially capitalized Simulated Environment Concepts Inc. with several million dollars of their own money. With this initial investment, the company worked on, and succeeded in developing, the sleek and stylish looking pressurized dry water massage relaxation station.

SpaCapsule® is a full body massage, aromatherapy, audio and video entertainment system. The capsules are fused with advanced modern technology and healing methods of aromatherapy and audiovisual relaxation techniques, incorporating proprietary water-jet and pressure-jet technology that requires no on-site plumbing. Weighing approximately 500 lbs, the capsule only requires standard electric service.

Simulated Environment Concepts anticipates progressive and consistent growth over the next six years. With individuals spending billions of dollars on de-stressing, weight loss, anti aging, cosmetics, massage and physical rehabilitations, the company is in a position to experience explosive growth from current levels. Disclaimer

Omnicity Corp (OMCY) Set To Triple Coverage

Omnicity Corp., known for bringing broadband communication service to underserved rural areas, has signed an agreement that will more than triple its coverage of marketable homes. The agreement is with leading international satellite Internet service provider StarBand Communications Inc., and allows Omnicity to offer StarBand satellite high speed Internet service coverage to areas throughout the U.S. not currently able to receive Omnicity’s wireless Internet or DSL services.

The new service will be rebranded as Omnicity Satellite Internet Services, and means Omnicity will have a high speed Internet solution for virtually every household in its markets. The service will be available for residential, small office/home office, and small business customers, and secures Omnicity’s position as the key player in the rural broadband service industry.

Omnicity CEO, Greg Jarman, commented on the importance of the agreement. “We have people who call in on a daily basis that we can’t reach yet with our wireless and DSL coverage areas. With our new satellite capabilities, we can cover just about everybody. By having some method to deliver high speed internet service to virtually every home in our service areas, either wireless, DSL, and now Omnicity Satellite Internet Services, we truly can strive for exceptionally high market penetrations and an outstanding branded Omnicity presence. This translates to higher revenue and cash flow per home passed through existing Omnicity assets and, of course, into great long-term value for our shareholders. We are very excited to have consummated this satellite delivery deal and to begin marketing Omnicity Satellite Internet Services alongside our wireless and DSL options.”

Omnicity plans to add the new satellite coverage during the second round of the American Recover and Reinvestment Act of 2009 to bring the Internet to all of rural America. The company’s strategy is to continue its rapid growth through acquisitions and organic growth, and to continue to partner with Rural Electric Membership Co-ops and Rural Telephone Companies.

Clenergen Corp. (CRGE) Reaches Agreement to Terms to Acquire 1.5MW Biomass Power Plant in Tamil Nadu, India

Today it was announced that Clenergen Corporation India Private Limited, a wholly owned subsidiary of Clenergen Corporation, has agreed on the terms to acquire a 1.5MW/Hr biomass power plant in Namakkal, Tamilnadu, which will be operational by yearend 2009.

Recognized as one of India’s National Demonstration Projects, the plant was shut down in 2007 due to operational cash flow constraints and its inability to remain profitable at a low tariff rate. However, under a Power Purchase Agreement between Power Trading Corporation of India Limited (PTC) and Clenergen India Private Limited, a higher tariff rate has now been agreed.

The unit is expected to generate net revenue of approximately US$1 million in its first year of operation. During the first phase of its operations in India, Clenergen will ramp up the capacity of this power plant to 10MW/Hr while installing two new biomass power projects: a 16MW/Hr in Tuticorin Tamilnadu and a 64MW/Hr in Karnataka. The total project cost of the new plants has been estimated at US$236 million.
Clenergen’s Tuticorin power plant is expected to be in commercial operation sometime in the last quarter of 2010. The company is proposing to raise US$83 million in equity financing from the Indian stock markets. The 16MW/Hr power plant will require 4,000 acres of land to cultivate biomass feedstock required for its 24/7 operation, of which 800 acres has already been secured under sublease. Until the cultivated feedstocks reach first harvest, local supplies of wood chips will be contracted.

Clenergen also announced that it has identified an efficient system of power generation using gasification technology/gas turbines generators and power generation through Pyrolisis/steam turbine generators. These systems can produce power, steam, hydrogen, chemicals and other important products through advanced gasification and Pyrolisis/combustion steam technologies. The company also produces high-density, short-rotation biomass crops on a commercial scale at a cost of production equivalent to or less than the price of coal (measured in energy terms – MMBtu) using a proprietary integrated farming model.

Announcing the company’s plans for India here at a press conference, Dr. Arvind Pandalai, Non Executive Group Chairman, said, “The Namakkal unit, which is entirely carbon neutral, successfully demonstrated the ‘anaerobic digestive technology’ to process agri-biomass to renewable energy. The unit has already been assessed for carbon credits.”

Dr Pandalai added, “Clenergen new biomass power plants at Tamil Nadu and Karnataka will be based on the feedstock of `Beema Bamboo’, a grass species, and `Marjestica’, a micro propagated species of Paulownia native to China and parts of Asia. The company has partnered with Growmore Biotech Limited, Hosur, for the production and supply of the micro propagated Beema Bamboo. Additionally, Clenergen has licensed a Tree Adaption Process that increases the growth rate of Majestica by up to 40% and will be conducting field trials of the improved strain in Tamilnadu in the first quarter 2010.


Sponsors of the Day

The QualityStocks Public Company Sponsor News

Advanced Visual Systems Inc. (AVSC) Advanced Visual Systems Celebrates 18 Years of Data Visualization Technology Leadership



About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-374-1336